Viral load in semen rapidly rebounds to infectious levels during HIV treatment breaks
Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men
Early HIV treatment reduces the risk of liver fibrosis
Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left
Gammora does not cure HIV
Dolutegravir plus darunavir maintains viral suppression without NRTIs
Reaching the men: who are the partners of the young women with HIV in South Africa?
Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows
How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects
